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ABSTRACT
Aims To examine long-term changes in environmental tobacco smoke (ETS) exposure in British men between 1978
and 2000, using serum cotinine.Design Prospective cohort: British Regional Heart Study. Setting General practices
in 24 towns in England, Wales and Scotland. Participants Non-smoking men: 2125 studied at baseline [question-
naire (Q1): 1978–80, aged 40–59 years], 3046 studied 20 years later (Q20: 1998–2000, aged 60–79 years) and 1208
studied at both times. Non-smokers were men reporting no current smoking with cotinine < 15 ng/ml at Q1 and/or
Q20. Measurements Serum cotinine to assess ETS exposure. Findings In cross-sectional analysis, geometric mean
cotinine level declined from 1.36 ng/ml [95% confidence interval (CI): 1.31, 1.42] at Q1 to 0.19 ng/ml (95% CI: 0.18,
0.19) at Q20. The prevalence of cotinine levels  0.7 ng/ml [associated with low coronary heart disease (CHD) risk]
rose from 27.1% at Q1 to 83.3% at Q20. Manual social class and northern region of residence were associated with
higher mean cotinine levels both at Q1 and Q20; older age was associated with lower cotinine level at Q20 only. Among
1208 persistent non-smokers, cotinine fell by 1.47 ng/ml (95% CI: 1.37, 1.57), 86% decline. Absolute falls in cotinine
were greater in manual occupational groups, in the Midlands and Scotland compared to southern England, although
percentage decline was very similar across groups.Conclusions A marked decline in ETS exposure occurred in Britain
between 1978 and 2000, which is likely to have reduced ETS-related disease risks appreciably before the introduction
of legislation banning smoking in public places.
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INTRODUCTION
Environmental tobacco smoke (ETS) exposure is an
important public health issue. Numerous epidemiological
studies have reported that ETS exposure is associated
with elevated risks of lung cancer [1] and cardiovascular
diseases in adults [2–4] and respiratory problems in chil-
dren [5]. ETS exposure comprises a mixture of sidestream
smoke from burning cigarettes and mainstream smoke
exhaled by active smokers. Sidestream smoke may be dis-
proportionately more harmful than mainstream smoke
[6]. ETS exposure in non-smoking populations is best
quantified by measuring cotinine (a stable metabolite of
nicotine measured in serum or saliva, which has a half-
life of 16–20 hours, and therefore quantifies recent
tobacco exposure [6]).
Between 1978 and 2000 marked changes in factors
affecting ETS exposure occurred in the United Kingdom.
The prevalence of active smoking in adults fell from 40%
to 27% and, among smokers, cigarette consumption
declined from 114 to 97 cigarettes/week [7]. Restrictions
on smoking both in public places and in work-places
increased; by 1997 82% adults reported work-place
smoking restrictions [8].
However, information on changes in ETS exposure in
the United Kingdom between 1978 and 2000 is very
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scarce. Evidence is limited to the Health Survey for
England (HSE), which reported a small rise in cotinine
levels of 0.04 ng/ml (11% increase) in adult non-
smokers between 1994 and 1996 [9]. In adolescents a
decline in cotinine levels of 0.44 ng/ml (46% fall) was
reported between 1988 and 1998 in 11–15-year-olds
[10].
We have therefore examined serum cotinine levels and
their determinants among non-smoking British men
studied in two cross-sectional surveys carried out within
a cohort study in 1978–80 and 1998–2000, and the
patterns of change in cotinine in a subset of men studied
on both occasions 20 years apart. We also examined the
proportion of non-smoking men at both time-points who
had a cotinine level of  0.7 ng/ml, a level associated
with low coronary heart disease (CHD) risk in our earlier
study [4]. In addition, we have examined the influence of
socio-demographic and household factors on levels and
changes in cotinine levels over this extended period.
METHODS
The British Regional Heart Study (BRHS) is a prospective
study of 7735 men (78% response rate) aged 40–59
years registered with one representative general practice
in each of 24 British towns [11]. At entry to the study in
1978–80 [questionnaire 1 (Q1)], nurses administered a
health and life-style questionnaire and took blood
samples. Men were asked in detail about current and pre-
vious smoking history (cigarettes, pipes and cigars),
occupation and medication use. Blood samples were
taken for all men; in 4735 men in 18 study towns refer-
ence samples were stored (-20°C) for subsequent analy-
ses including cotinine. In 1998–2000 (Q20) 4252 of
5699 surviving men (77% response rate), now aged
60–79 years, attended for a further assessment, includ-
ing a questionnaire survey and the collection of blood
samples [11]; cotinine assays were completed in 3900
subjects from all 24 towns. Cotinine measurements at
both time-points were available for 2347 men. Baseline
serum samples (1978–80) were assayed for cotinine
in 2000–01 and follow-up samples (1998–2000) in
2007–08 at the same laboratory (ABS Laboratories Ltd,
London, UK). The same method was used in non-smokers
on both occasions: a liquid chromatography tandem
mass spectrometry (LC MS/MS) assay with a lower limit
of detection of 0.02 ng/ml with a limit of quantification
of 0.1 ng/ml [12]. No men in the sample reported taking
nicotine replacement therapy at Q20 [British National
Formulary (BNF) code 4.10] [13]. Ethical approval was
provided by all relevant local research ethics committees.
Non-smokers were men who reported no current
smoking (cigarette, cigar or pipe smoking) and had serum
cotinine 15 ng/ml, as in other literature [9]. Men who
reported being non-smokers but with cotinine > 15 ng/m
were recoded as smokers (n = 58 of 2183 at Q1 and
n = 58 of 3104 at Q20). Social class was based on
longest-held occupation of each man at Q1, classified
according to the Registrar General scales: I, II, III non-
manual, III manual, IV and V. Men in the armed forces
(n = 231) were treated as a separate group and were
excluded from analyses of trends by social class. Employ-
ment status at Q1 and Q20 was coded as employed or not
(unemployed plus retired). Region of residence at study
entry was defined as Scotland, North, Midlands and
South, as in previous studies [14]. At Q20 men recorded
their spouse’s smoking habits as current, ex-smokers or
non-smokers and the number of hours per day that they
were exposed to cigarette smoke (i) at home, grouped as
none or rarely, 1–5, 6–24 hours; and (ii) elsewhere,
grouped as none or rarely, 1–3, 4–24 hours.
Statistical methods
The distributions of cotinine values (although not
changes in cotinine values) were positively skewed, there-
fore geometric means and 95% confidence intervals (CI)
are reported. Cotinine values below the limit of quantifi-
cation were assigned a value of 0.05 ng/ml, the mid-
point between the limit and zero exposure, as in other
studies [10].
Geometric mean (95% CI) cotinine levels at Q1 and at
Q20 were calculated for each age-group, occupational
group and region of residence at study entry, and (at Q20
only) partner’s smoking group. Mutually adjusted geo-
metric mean cotinines were then calculated from linear
regression models which regressed log cotinine on
explanatory variables. Additionally, geometric mean coti-
nine at Q20 was calculated according to number of hours
exposed to cigarette smoke at home, among the men
living with a smoker at Q20. To compare the cotinine
distribution in non-smokers at Q1 with Q20, natural log
cotinine values were plotted against age for both surveys.
The intra-individual absolute change in cotinine level
between the two surveys was calculated as (cotinine
Q20–cotinine Q1) in the 1208 non-smokers with coti-
nine data at both surveys. It was approximately normally
distributed and was modelled using linear regression in
relation to covariates including age at study entry, occu-
pational position, region of residence and partner’s
smoking habit. Additionally, the percentage change
between adjusted geometric means, calculated as
100 ¥ [(Q20 - Q1)/Q1], was reported for each level of
the covariates.
RESULTS
Baseline (Q1) analyses are based on 4636 men with both
questionnaire smoking history and cotinine levels in
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1978–80, of whom 2125 (46%) were non-smokers.
Follow-up (Q20) analyses are based on 3784 men with
both questionnaire smoking history and cotinine levels in
1998–2000, of whom 3046 (81%) were non-smokers.
Questionnaire smoking history and cotinine data were
available at both time-points on 2272 men; of these,
1208 (53%) were non-smokers on both occasions.
Cross sectional analysis
In cross-sectional analyses at the two time-points, geo-
metric mean cotinine was 1.36 ng/ml (95% CI: 1.31,
1.42) in 1978–80 and 0.19 ng/ml (95% CI: 0.18, 0.19)
in 1998–2000, a decline of 1.17 ng/ml (86%). Figure 1
illustrates the cotinine levels in non-smokers in relation
to age at Q1 and Q20. There was a marked decline in
cotinine levels between the two surveys; at Q1 cotinine
did not vary with age, but at Q20 there was a weak
inverse association between cotinine and age. The distri-
bution of exceptionally low cotinine values also increased
markedly between the two time-points. At Q1 only 0.5%
(95% CI: 0.3, 0.9) (n = 11/2125) of men had cotinine
levels less than or equal to the level of detection, com-
pared to 35.1% (95% CI: 33.4, 36.8) (1069/3046) at
Q20. The proportion of men with a cotinine level of
0.7 ng/ml increased from 27.1% (95% CI: 25.2, 29.0)
(575/2125) at Q1 to 83.3% (95% CI: 81.9, 84.6) (2536/
3046) at Q20.
The socio-demographic correlates of cotinine in non-
smokers were examined at both time-points (Table 1).
Age at Q1 (40–59 years) was not associated with cotinine
at Q1, but at Q20 (60–79 years) younger men had higher
mean cotinine levels. Men in manual occupational
groups, in employment or living in northern England had
higher mean cotinine levels, both at Q1 and at Q20.
Mutual adjustment for age, class, employment status and
region did not change materially the group means or
linear trends. At Q20, additional information was avail-
able about spouse smoking habits; men who lived with
current smokers had almost eight times higher adjusted
geometric mean cotinine values than men who lived with
non-smokers [1.19 ng/ml (95% CI: 1.04, 1.34) versus
0.15 ng/ml (95% CI: 0.14, 0.15), respectively]. Men also
reported the number of hours per day that they were
exposed to tobacco smoke in the home. Among non-
smokers who lived with a smoker, exposure to smoke for
1–5 hours per day was associated with cotinine levels
double that of with men reporting little or no exposure
and nearly 10 times that of men who did not live with a
smoker [1.39 ng/ml (95% CI: 1.15, 1.69) versus
0.67 ng/ml (95% CI: 0.53, 0.86) versus 0.15 ng/ml
(95% CI: 0.15, 0.16), respectively]. There was evidence
for dose-dependent associations of increasing cotinine
with increasing ETS exposure both at home and else-
where. Reporting more than 1 hour of exposure to smoke
elsewhere was associated with more than double the
cotinine levels in men with none/rare exposure. The
adjustment for age, social class, employment and
region attenuated the mean values slightly. Among
non-smokers with cotinine > 0.7 ng/ml and data on self-
reported exposure at Q20, 50% lived with a partner who
smoked; of these 80% reported 1 hour/day exposure to
ETS at home and 40% reported  1 hour/day exposure
ETS elsewhere than at home (data not presented).
Longitudinal analysis
Cotinine levels were investigated in 1208 persistent non-
smokers with cotinine < 15 ng/ml at both Q1 and Q20.
The geometric mean cotinine levels of these men were
were 1.23 ng/ml (95% CI: 1.17, 1.30) at Q1 and
0.16 ng/ml (0.15, 0.17) at Q20. These values were
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Figure 1 Association between serum
cotinine and age in non-smokers at
questionnaire 1 (Q1) (1978–80) and
Q20 (1998–2000)
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Table 1 Adjusted geometric mean [95% confidence interval (CI)] cotinine level in non smokers at (i) questionnaire 1 (Q1) and (ii) Q20
by demographic factors.
n (%)
Cotinine at Q1
(age 38–61 years)a n (%)
Cotinine at Q20
(age 58–81 years)a
Grand mean 2125 (100) 1.36 (1.31, 1.42) 3046 (100) 0.19 (0.18, 0.19)
Age (years)
Q1: 38–44, Q20: 58–64 516 (24.3) 1.40 (1.29, 1.52) 930 (30.5) 0.20 (0.18, 0.21)
Q1: 45–49, Q20: 65–69 519 (24.4) 1.27 (1.17, 1.38) 869 (28.5) 0.19 (0.18, 0.20)
Q1: 50–54, Q20: 70–74 524 (24.7) 1.39 (1.29, 1.51) 718 (23.6) 0.19 (0.17, 0.20)
Q1: 55–61, Q20: 75–81 566 (26.6) 1.39 (1.29, 1.51) 529 (17.4) 0.17 (0.15, 0.18)
P(trend)b 0.665 < 0.001
Class at Q1
I 244 (11.5) 1.03 (0.92, 1.16) 313 (10.3) 0.15 (0.14, 0.17)
II 536 (25.2) 1.22 (1.13, 1.32) 849 (27.9) 0.16 (0.15, 0.18)
III NM 197 (9.3) 1.20 (1.05, 1.37) 313 (10.3) 0.17 (0.15, 0.19)
III M 79 (3.7) 1.80 (1.46, 2.23) 89 (2.9) 0.25 (0.20, 0.31)
IV M 850 (40.0) 1.49 (1.39, 1.59) 1169 (38.4) 0.21 (0.20, 0.22)
V M 179 (1.9) 1.76 (1.53, 2.02) 242 (7.9) 0.21 (0.18, 0.24)
Armed forces 40 (1.9) 1.77 (1.32, 2.37) 71 (2.3) 0.21 (0.17, 0.27)
P(trend)b < 0.001 < 0.001
Employment (at Q1, at Q20)
Employed 2033 (95.7) 1.38 (1.32, 1.44) 226 (18.7) 0.20 (0.18, 0.22)
Not employed 92 (4.3) 1.07 (0.88, 1.30) 939 (77.8) 0.18 (0.18, 0.19)
Missing 0 (0) 99 (2.3) 0.16 (0.12, 0.21)
P(trend)b 0.027 0.006
Region at Q1
South 780 (36.7) 1.04 (0.97, 1.11) 1076 (35.5) 0.15 (0.15, 0.17)
Midlands 104 (4.9) 1.69 (1.41, 2.03) 479 (15.7) 0.19 (0.18, 0.21)
North 877 (41.3) 1.49 (1.40, 1.58) 1171 (38.4) 0.20 (0.19, 0.21)
Scotland 364 (17.1) 1.88 (1.70, 2.07) 320 (10.5) 0.24 (0.21, 0.26)
P(trend)b < 0.001 < 0.001
Spouse smoking at Q20
Non-smoker 2262 (74.3) 0.15 (0.14, 0.15)
Ex-smoker 226 (7.4) 0.19 (0.17, 0.22)
Smoker 275 (9.0) 1.19 (1.04, 1.34)
NA (no spouse) 168 (5.5) 0.19 (0.17, 0.23)
Missing 115 (3.8) 0.18 (0.14, 0.22)
P(trend)b < 0.001
Hours/day exposed to ETS at home at Q20
None/rare 2764 (90.9) 0.15 (0.15, 0.16)c
None/rare and partner smokes 73 (2.4) 0.67 (0.53, 0.86)c
1–5 118 (3.9) 1.39 (1.15, 1.69)c
6–24 64 (2.1) 1.83 (1.40, 2.38)c
Missing 21 (0.7) 0.95 (0.60, 1.50)c
P(trend)b < 0.001
Hours/day exposed to ETS elsewhere at Q20
None/rare 2335 (76.7) 0.16 (0.15, 0.17)
1–3 223 (7.3) 0.38 (0.33, 0.43)
4–24 80 (2.7) 0.47 (0.37, 0.59)
Missing 408 (13.4) 0.25 (0.22, 0.28)
P(trend)b < 0.001
aCotinine at Q1 adjusted for age, class, employment status and region; cotinine at Q20 adjusted for age, class, employment status, region, spouse
smoking and hours/day exposed to environmental tobacco smoke (ETS) outside home; btrend tests from separate linear regression models. Missing
group/armed forces excluded from test; cadjusted model includes age, class, employment status, region, hours/day exposed to ETS at home and
elsewhere. NA: not applicable.
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slightly lower than those in the two cross-sectional
surveys as a whole (1.36 ng/ml at Q1, 0.19 ng/ml at
Q20), although the percentage decline in the longitudi-
nal population (87%) was nearly identical to that in the
two cross-sectional surveys (86%). The longitudinal
sample contained a higher proportion of professional/
managerial workers (40.3%) than did the longitudinal
sample of non-smokers (36.7%). In the 1208 non-
smoking men studied both at Q1 and Q20, baseline and
follow-up cotinine values were correlated moderately
(r = 0.35). The absolute change in cotinine level and its
determinants are presented in Table 2. The size of decline
was unrelated to age, but was greater among men in
manual compared to non-manual occupational groups
and in men in the Midlands and Scotland compared to
southern England; these falls were little affected by
mutual adjustment. The overall proportional fall in coti-
nine (87%) was, however, very similar in all age-groups,
social classes and regions (Table 2). Thus, although abso-
lute falls in cotinine level were greater in men from social
class V (manual) than social class I (professional)
(2.10 ng/ml compared with 1.13 ng/ml, respectively),
proportional falls were very similar (89% and 87%,
respectively).
All analyses were repeated using a more recently rec-
ommended and more conservative cotinine threshold of
9.5 ng/ml [21] to identify non-smokers, and this did not
affect the results materially.
DISCUSSION
In this study of middle-aged and older British men, a
marked decline in ETS exposure occurred between 1978
and 2000, with mean cotinine levels falling by 86% from
1.36 ng/ml to 0.19 ng/ml. The prevalence of cotinine
levels sufficiently high to cause adverse cardiovascular
consequences > 0.7 ng/ml [5] fell from 83% to 27%.
Social class and region were related independently to coti-
nine levels both in 1978 and in 2000. The men with the
highest levels of exposure in 1978 (i.e. men in more
manual occupations and those living further north in the
United Kingdom) experienced the greatest absolute
decline in exposure up to 2000, although the percentage
changes were similar.
Comparison of cotinine levels with other data
There are limited data on cotinine levels in British adults
in the 1978–2000 period. In the Scottish Heart Health
Table 2 Changes in cotinine level (expressed as mean and proportion) between 1978–80 and 1998–2000 among non-smokers:
influence of age, social class and region (n = 1208).
Non smokers Q1–Q20
Unadjusted cotinine change Q1–Q20 Mutually adjusted cotinine change Q1–Q20b % change Q1–Q20c
Grand mean -1.47 (-1.57, -1.37) -1.47 (-1.56, -1.37) -87
Age (years) at Q1
38–44 -1.52 (-1.71, -1.34) -1.50 (-1.68, -1.31) -86
45–49 -1.46 (-1.65, -1.28) -1.49 (-1.67, -1.31) -88
50–54 -1.35 (-1.56, -1.15) -1.37 (-1.57, -1.17) -85
55–61 -1.53 (-1.76, -1.30) -1.52 (-1.74, -1.30) -89
P(trend)a 0.735 0.740
Class at Q1
I and II -1.02 (-1.29, -0.76) -1.13 (-1.39, -0.86) -87
II -1.36 (-1.55, -1.17) -1.37 (-1.55, -1.18) -88
III NM -1.34 (-1.65, -1.04) -1.36 (-1.66, -1.05) -89
III M -1.93 (-2.51, -1.35) -1.83 (-2.41, -1.25) -88
IV M -1.58 (-1.74, -1.42) -1.54 (-1.70, -1.38) -85
V M -2.13 (-2.49, -1.78) -2.10 (-2.46, -1.75) -89
Armed forces -1.22 (-1.95, -0.50) -1.32 (-2.05, -0.61) -87
P(trend)a < 0.001 < 0.001
Region at Q1
South -1.17 (-1.32, -1.01) -1.22 (-1.37, -1.06) -87
Midlands -1.87 (-2.13, -1.61) -2.10 (-2.60, -1.60) -93
North -1.59 (-1.74, -1.43) -1.55 (-1.70, -1.39) -86
Scotland -1.75 (-1.99, -1.50) -1.73 (-1.97, -1.49) -87
P(trend)a < 0.001 < 0.001
aTrend tests all from separate linear regression models; bmeans adjusted for age, social class and region; c% change calculated as [adjusted geometric
mean questionnaire 1 (Q1)—adjusted geometric mean Q20/adjusted geometric mean Q1] in 1208 men who were non-smokers at Q1 and Q20. Means
adjusted for age, region and class only.
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Study (SHHS), median serum cotinine in all male non-
smokers aged 40–59 years studied in 1984–86 was 0.68
ng/ml [15], somewhat lower than the levels in the BRHS
in 1978–80 (1.36 ng/ml). In the national HSE, geomet-
ric mean plasma cotinine in 1994–96 combined was
0.42 ng/ml [9], about twice the level observed in BRHS in
1998–2000 (0.19 ng/ml). The decline seen in BRHS data
is consistent with a report based on salivary cotinine
measurements (which estimates cotinine levels about
25% higher than those in blood [16]) in the HSE and
Scottish Health Survey, in which mean salivary cotinine
levels in adults with a non-smoking partner fell by
slightly more than a half between 1993 [0.58 ng/ml
(95% CI: 0.56–0.61)] and 2003 [0.25 (95%: CI 0.23–
0.27)], although declines were not evident in homes
where adults smoked [17]. The proportion of adults with
cotinine levels below detectable levels has also increased
over the study period: in SHHS in 1984–86 more than
one-quarter of non-smoking participants had no mea-
surable cotinine level, compared with 0.5% men in BRHS
about 6 years earlier. This evidence, although incomplete,
suggests that the marked secular decline observed in
BRHS has probably taken place gradually during the
1980s and 1990s; this would be consistent with the
secular decline observed in salivary cotinine levels in
British school children, in whom levels fell gradually
between 1988 and 1998, from 0.96 mg/nl to 0.52 (0.43,
0.62) [10]. In the National Health and Nutrition Exami-
nation Study (NHANES) study in the United States,
broadly similar patterns are seen. Between 1988–91 and
2001–2, cotinine levels in non-smoking adults (aged over
20 years) fell by 70% to a level of 0.035 ng/ml (95% CI:
0.035, 0.060), lower than that seen in BRHS. The preva-
lence of undetectable cotinine levels rose from 12% in
1988–91 to 67% in 2001–02 [18].
Manual social groups and northern regions had the
highest initial levels and greatest absolute decline in coti-
nine in BRHS. Similar cross-sectional relations between
social class, region and cotinine levels have been reported
in HSE [9]. Similar differences in patterns of decline
between different social class groups were observed in
NHANES data in the United States over a shorter time-
period (1988–2002) [19]. These patterns and differences
almost certainly reflect the social class and regional differ-
ences in prevalence of cigarette smoking and subsequent
changes in smoking prevalence [8]. The higher cotinine
levels of non-smokers living with a smoker in BRHS in
1998–2000 are broadly consistent with 1994–96 HSE
data and 1996–2003 HSE/Scottish Health Survey data.
In BRHS, cotinine levels were nearly eight times higher
among men living with a partner who smoked compared
to a non-smoker; 1.19 ng/ml (1.04, 1.34) compared to
0.15 ng/ml (0.14, 0.15). In HSE, non-smoking adults
cohabiting with another non-smoker had adjusted mean
serum cotinine levels of 0.34 ng/ml; own cotinine level
increased with increasing partner’s cigarette consump-
tion (up to 3.5-fold for smokers of > 30/day) [9]. In com-
bined HSE/Scottish Health Survey data, salivary cotinine
was nearly five times greater in adults in a smoking
home compared to adults from a non-smoking home:
1.46 ng/ml compared to 0.31 ng/ml [17].
Strengths and weaknesses
The present study is unique in quantifying changes in
ETS exposure in British men over an extended (20 years)
period using an objective biomarker (cotinine) to
measure exposure. The use of serum cotinine rather than
self-report to quantify ETS exposure is a considerable
strength. It is well validated for this purpose [6] and is
stable over extended periods, so levels are unlikely to have
been affected by long-term storage. Although there is
genetic variation in cotinine metabolism [20], this would
not be expected to affect the intra-individual changes in
cotinine levels. Most other studies have been based on
much shorter time-periods. Although there were appre-
ciable losses to follow-up during the study, the assess-
ments of changes in ETS exposure and its determinants
are unlikely to have been influenced seriously by selection
bias. Bias is unlikely, given that the percentage decline in
cotinine in the longitudinal sample was almost the same
as the change in the cross-sectional samples and, further,
that baseline (Q1) cotinine levels of non-smokers who
survived to Q20 were only slightly lower than in non-
smokers who did not survive to Q20: 1.51 ng/ml (95%
CI: 1.44, 1.59) compared to 1.85 (95% CI: 1.63, 2.09).
Moreover, under-representation of men from manual
social classes in the longitudinal analyses was slight.
However, the inverse association between age and coti-
nine level in the follow-up study, suggesting that men
aged 75–81 years may have systematically lower ETS
exposure than younger men, raises the possibility that the
overall decline in exposure has been slightly overesti-
mated by including these older men. However, even for
the oldest age-group, the proportional decline in cotinine
is only slightly higher (89%) than in the youngest age-
group (86%). Although we study men, overall patterns
are likely to be very similar in women, although ETS
exposure is likely to have been slightly lower in women.
Other studies reported lower levels of cotinine exposure
in non-smoking women than in non-smoking men
[9,18]. The sensitivity analysis demonstrated the robust-
ness of the results using a more conservative cotinine
threshold to identify non-smokers [21].
Implications of the results
The results show clearly that there was a very marked
decline in ETS exposures among non-smokers in Britain
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between 1978 and 2000, well before the legislative bans
on smoking in public places implemented in England,
Scotland and Wales between 2006 and 2007. This
decline was probably gradual and is likely to have had
several causes, although their relative importance is dif-
ficult to assess. First, the prevalence of active smokers
declined during this period, so the men were exposed to
smoke from fewer people. By 2000, only 14% of men in
the study were cigarette smokers (compared with 54%
in 1978–80) and only 13% lived with a partner who
currently smoked. Secondly, the number of cigarettes
smoked by active smokers has declined. Both trends are
expected to affect ETS exposure of non-smoking adults at
home and at leisure. Thirdly, the period covered by this
study includes increasing restrictions on smoking, par-
ticularly in the work-place, with 82% adults reporting
work-place smoking restrictions by 1997 [8]. The results
do not suggest that ageing or retirement of the cohort
underlies the observed decline in cotinine levels. Age was
not associated with cotinine at Q1 and only weakly at
Q20 (a difference of 0.03 ng/ml across the 23-year age
range). At both Q1 and Q20 men in employment had
higher cotinine levels than unemployed or retired men.
However, the difference in mean cotinine levels by
employment status (0.31 ng/ml at Q1 and 0.02 ng/ml at
Q20) is much smaller than the difference in grand means
(1.17 ng/ml) over the 20-year period, suggesting that
ageing and retirement were not major determinants of
observed cotinine decline over the study period.
The impact of the decline in ETS exposure on adult
health is difficult to quantify. Although measurement of
cotinine allows accurate quantification of ETS exposure,
data on the relationship of cotinine levels to health out-
comes among non-smokers are limited. In a previous
study, we showed that in non-smokers cotinine levels
above 0.7 ng/ml at Q1 were associated with elevated risks
of CHD over a 20-year period [4]. The marked decline in
average cotinine levels observed between 1978 and 2000
was accompanied by a very marked decline in the propor-
tion of non-smokers with cotinine levels above 0.7 ng/
ml, which declined from 83% in 1978–80 to 27% in
1998–2000. On the basis of our earlier report on the
relations of cotinine exposure to CHD risk [4], the decline
in the proportion of subjects with a cotinine level of more
than 0.7 ng/ml could have accounted for a decline in
CHD risk of about 20% over the study period. However, it
is possible that the rapid decline in ETS exposure led us to
underestimate the risks of CHD associated with ETS expo-
sure, a point we made in our earlier paper [4], in which
case the contribution of declining ETS exposure to the
documented decline in CHD risk [22] may also have been
underestimated. However, studies linking cotinine level
with intermediate vascular risk markers have suggested
that levels of cotinine as low as 0.2 ng/ml could be asso-
ciated with increased CHD risk [23]. If this were the case,
it would suggest that, although substantial reductions in
cotinine-related risk occurred between 1978 and 2000,
further reductions in cotinine levels would be necessary
to abolish associated health risks completely.
It is likely that over the 20-year period there has been
a shift in the balance of ETS exposure sources. At Q1 a
substantial proportion of the ETS exposure arose outside
the home, in the work-place and other public spaces
including pubs and restaurants, although during the
20-year follow-up exposure in the work-place was
removed progressively, particularly in this older popula-
tion who are mainly retired and have left the work-place.
The important role of the home as a continuing source of
ETS exposure is emphasized by the 1998–2000 BRHS
survey, in which half the non-smokers with cotinine
> 0.7 ng/ml lived with a partner who smoked. There was
also a strong association between hours of domestic
exposure and cotinine levels among men living with
smokers; average cotinine levels in men living with a
smoker were similar to those of all non-smoking men 20
years previously. Although this population, being retired,
may overestimate the relevance of domestic exposure for
the whole population, home exposure is likely to be the
dominant exposure source. This situation is likely to have
been reinforced by the subsequent national bans on
smoking in public places, which by reducing ETS expo-
sure in public places and work-places [24] emphasizes
the relative importance of domestic exposure as a source
of residual ETS exposure. Importantly, it is not thought
that domestic exposure within smoking households rises
in response to public smoking bans [25]. After the
smoking ban in Scotland, cotinine levels remained stable
among those living in households with smokers, while
levels declined among non-smoking adults living in non-
smoking households [24].
Our present and previous studies suggest that there is
potential for further health gain from additional reduc-
tions in ETS exposure, aiming particularly to reduce
further the prevalence of non-smoking subjects with a
cotinine level of > 0.7 ng/ml. Such reductions are likely
to depend upon further reducing domestic ETS exposure.
CONCLUSIONS
Substantial declines in ETS exposure were observed
between 1978 and 2000, which probably reflect a steady
decline over the period and are likely to have had appre-
ciable effects on CHD risk. The decline in exposure prob-
ably reflects decreased smoking prevalence and amounts
smoked, and restrictions on smoking in work-places.
Further reductions in ETS exposure are likely to require
greater efforts to limit exposure in the home.
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